Edition:
United States

Ignyta Inc (RXDX.OQ)

RXDX.OQ on NASDAQ Stock Exchange Capital Market

16.00USD
9:59am EST
Change (% chg)

$0.05 (+0.31%)
Prev Close
$15.95
Open
$16.05
Day's High
$16.10
Day's Low
$15.90
Volume
15,072
Avg. Vol
241,369
52-wk High
$18.25
52-wk Low
$4.65

Latest Key Developments (Source: Significant Developments)

Ignyta Q3 loss per share $0.51
Tuesday, 7 Nov 2017 04:00pm EST 

Nov 7 (Reuters) - Ignyta Inc ::Ignyta announces third quarter 2017 company highlights and financial results.Q3 loss per share $0.51.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Ignyta Inc - qtrly ‍loss per share $0.51​.Ignyta Inc says ‍ignyta did not record any revenue for Q3 of 2017 or for Q3 of 2016​.  Full Article

Ignyta says public offering of 10.0 million common shares priced at $16.00per share
Thursday, 19 Oct 2017 09:01pm EDT 

Oct 19 (Reuters) - Ignyta Inc ::Ignyta announces pricing of public offering of common stock.Says public offering of 10.0 million common shares priced at $16.00per share.  Full Article

Ignyta Inc files for potential mixed shelf offering; size not disclosed
Wednesday, 18 Oct 2017 04:32pm EDT 

Oct 18 (Reuters) - Ignyta Inc :Ignyta Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​.  Full Article

Ignyta announces proposed public offering of common stock
Wednesday, 18 Oct 2017 04:23pm EDT 

Oct 18 (Reuters) - Ignyta Inc :Ignyta announces proposed public offering of common stock.Ignyta Inc says ‍commenced an underwritten public offering of $125.0 million of shares of its common stock​.Ignyta Inc says ‍anticipates using net proceeds from offering to fund research and development activities for its development programs​.  Full Article

Ignyta says Cormorant Asset Management LLC reports 5.3 pct passive stake in co
Monday, 11 Sep 2017 04:26pm EDT 

Sept 12 (Reuters) - Ignyta Inc :Cormorant Asset Management LLC reports 5.3 percent passive stake in Ignyta Inc as of August 31, 2017 - SEC filing.  Full Article

Ignyta provides update on entrectinib and RXDX-105 at the ESMO 2017 Congress
Monday, 11 Sep 2017 08:00am EDT 

Sept 11 (Reuters) - Ignyta Inc :Ignyta provides update on entrectinib and RXDX-105 at the esmo 2017 congress.Ignyta -‍confirms completion of enrollment of efficacy data sets for both NTRK tissue-agnostic cohort,ros1 nsclc cohort to support dual NDA submissions in 2018​.Ignyta Inc - ‍RXDX-105 phase 1b study will be concluded with no further enrollment; those currently receiving treatment will remain on study​.Ignyta Inc - ‍will continue discussing RXDX-105 with potential partners and will provide an update on the program in first half of 2018​.  Full Article

Ignyta Q2 loss per share $0.56
Tuesday, 8 Aug 2017 04:00pm EDT 

Aug 8 (Reuters) - Ignyta Inc :Ignyta announces second quarter 2017 company highlights and financial results.Q2 loss per share $0.56.Q2 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.  Full Article

Ignyta receives FDA orphan drug designation for entrectinib
Monday, 10 Jul 2017 07:00am EDT 

July 10 (Reuters) - Ignyta Inc ::Ignyta receives FDA orphan drug designation for entrectinib for treatment of NTRK fusion-positive solid tumors.Ignyta Inc - ‍FDA has granted orphan drug designation to entrectinib​.  Full Article

FDA grants Ignyta breakthrough therapy designation for entrectinib
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Ignyta Inc :Ignyta granted breakthrough therapy designation for entrectinib by U.S. Food and Drug Administration.  Full Article

Ignyta prices offering of 12.5 mln shares at $6.15/share
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Ignyta Inc :Ignyta announces pricing of public offering of common stock.Says public offering of 12.5 million common shares priced at $6.15per share.  Full Article

BRIEF-Ignyta announces new data highlighting immune modulation of RXDX-106 at the society for immunotherapy of cancer meeting

* Ignyta announces new data highlighting immune modulation of RXDX-106 at the society for immunotherapy of cancer (sitc) meeting Source text for Eikon: Further company coverage: